Category: From KIF1A.ORG

We have a special edition of Monthly Momentum for you with Pre-Conference presentations from our therapeutic development collaborators available for you to watch now! We are blown away by all that has transpired over the last 6 months and what is still to come for the rest of 2021. The KIF1A community has experienced growth…

KIF1A.ORG Community, We are thrilled to introduce you to BioLoomics, a new partner in our urgent mission to find treatments for KIF1A-Associated Neurological Disorder (KAND). BioLoomics uses their technology to speed up therapeutic discovery and yield promising drugs that cannot be found through traditional approaches. As we work relentlessly to outpace the ticking clock of…

What a month! In May we surpassed our $100,000 USD fundraising goal to accelerate KAND therapeutic development, introduced a new partner: Good Dogg Beverage, welcomed Summer Interns, opened the KAND Conference registration, and even more. Learn more about the progress we’ve made in this Monthly Momentum update.

KIF1A.ORG Community, We are excited to introduce you to Good Dogg Beverage, a new philanthropic company that makes premium hard seltzer to support causes they care about, like KIF1A.ORG. As a purpose-driven company, Good Dogg Beverage is a rare hard seltzer maker that stands out from the rest. Their goal is to make a positive…

KIF1A.ORG Community, Please help us welcome two interns from the M.A. Program in Biotechnology at Columbia University: Jerry Shen and Michelle Tao! We’re excited to have Jerry and Michelle share their skills and experience with KIF1A.ORG this summer to help advance our mission!

KIF1A.ORG Community, We’re eager to announce the expansion of our efforts to find treatments for KIF1A-Associated Neurological Disorder (KAND) by partnering with the Gennerich Lab at Albert Einstein College of Medicine in New York. Arne Gennerich, Ph.D., is an active member of the KIF1A Research Network and an expert in molecular mechanisms of microtubule-based motor…

KIF1A.ORG Community, KIF1A.ORG is excited to expand our pipeline of therapeutic development projects for KIF1A Associated Neurological Disorder (KAND) through our partnership with Rarebase. Rarebase is a public benefit corporation pioneering a new approach to biotech by partnering with patient communities like ours. They share our sense of urgency and optimism in today’s science to…

Another year has come and gone, and despite the changes and challenges that this year brought for many, the KIF1A.ORG community continued to experience exponential growth thanks to people like you. Real growth. Tangible growth. Growth that will allow THIS generation of individuals living with KIF1A Associated Neurological Disorder (KAND) to realize dreams, gain independence…

KIF1A.ORG introduces a new program to bring support and comfort to KIF1A superheroes undergoing a medical procedure or recovering from an injury. Read on to learn more about this new resource made possible by a partnership with Ryan’s Case for Smiles and Phillies Charities, Inc.

KIF1A.ORG Community, What if KIF1A treatment already existed? It could be on the shelves of your local pharmacy, or a drug created for a related disease like Parkinson’s or epilepsy. Are there FDA-approved treatments for other conditions that could bring relief to KAND patients living with progressive spasticity, uncontrolled seizures or painful neuropathy? We won’t…

KIF1A.ORG Community, Today we’re highlighting the exciting work we’re doing with Albany Molecular Research Inc. (AMRI) to support KIF1A.ORG’s therapeutic development efforts. This project was made possible by a Rising Tides grant awarded by The Child Neurology Foundation to support organizations during the COVID-19 pandemic.